EQT in Advanced Talks to Buy Qiagen in Potential $10 Billion Deal
EQT has submitted a binding offer of more than $50 per share for Qiagen in a potential $10 billion takeover. KKR has also bid as shares jump.
/ 5 items
#QGEN↓
Qiagen Sale Speculation: KKR, EQT and the $50 Question
Qiagen reviews options with Goldman and Moelis.
Qiagen Draws Early Takeover Interest from EQT, Advent, and KKR
No formal bids yet as the ~$9B molecular diagnostics leader faces sector consolidation.
Qiagen Considers Sale as Takeover Interest Returns
Qiagen is reviewing strategic options, including a possible sale, as takeover interest resurfaces in the fast-growing life sciences and diagnostics sector.
QIAGEN Acquires Parse Biosciences to Boost Single-Cell Research Capabilities
QIAGEN announces its $225 million acquisition of Parse Biosciences, expanding into scalable single-cell technologies to power AI-driven biological research and drug discovery.